Skip to main content
Essential Thrombocythemia (ET) Management: A Quiz Journey

ET Management Question 2


The correct answer is balance the expected thrombotic benefit against bleeding risk when considering therapy because cardiovascular risk factors and bleeding risks should both be integrated in treatment selection. In this case, the patient is less than 60 years of age, has not had a thrombosis, so would be technically classified as a low-risk patient. However, the patient has multiple cardiovascular risk factors and a markedly elevated platelet count with evidence of epistaxis.

This is a patient in which I would employ cytoreductive therapy and would likely favor interferon alfa-2b here, not just to reduce the platelet count, to reduce the risk of the acquired von Willebrand that can associate with an elevated platelet count, but also to address the potential thrombotic complications that can ensue in this patient with significant cardiovascular risk. It is important that aspirin plays a role, particularly when the platelets have been reduced, as a prophylactic, but one also needs to address the modifiable cardiovascular risk factors in patients with ET. Simply focusing on blood count control is only half the picture. It is important to also address the other comorbidities that can contribute to thrombotic risk in this setting. 

Take the next quiz. 

References

  1. Tefferi A, Gangat N, Loscocco GG, et al. Essential thrombocythemia: a review. JAMA. 2025;333(8):701. doi:10.1001/jama.2024.25349 
  2. Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(4):697-718. doi:10.1002/ajh.27216 
  3. Godfrey AL, Green AC, Harrison CN. Essential thrombocythemia: challenges in clinical practice and future prospects. Blood. 2023;141(16):1943-1953. doi:10.1182/blood.2022017625 
  4. Sever M, Newberry KJ, Verstovsek S. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. Leuk Lymphoma. 2014;55(12):2685-2690. doi:10.3109/10428194.2014.893310 
  5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms V.3.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed October 15, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 
  6. Mesa R, Gill H, Zhang L, et al. Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS-ET): a multicentre, open-label, randomised, active-controlled, phase 3 study. Lancet Haematol. 2025;12(11):e862-e875. doi:10.1016/S2352-3026(25)00264-9 
  7. Awada H, Voso M, Guglielmelli P, Gurnari C. Essential thrombocythemia and acquired von Willebrand syndrome: the shadowlands between thrombosis and bleeding. Cancers. 2020;12(7):1746. doi:10.3390/cancers1207174 
  8. Park YH, Lee S, Mun Y, Park DJ. Prognostic value of modified criteria for hydroxyurea resistance or intolerance in patients with high‐risk essential thrombocythemia. Cancer Med. 2023;12(7):8073-8082. doi:10.1002/cam4.5602 
  9. Reilly JT, McMullin MF, Beer PA, et al. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol. 2012;158(4):453-471. doi:10.1111/j.1365-2141.2012.09179.x 
  10. Tremblay D. Cytoreduction for ET and PV: who, what, when, and how? Hematol Am Soc Hematol. 2023;2023(1):660-666. doi:10.1182/hematology.2023000451 
  11. Abu-Zeinah G, Hobbs GS, Rampal RK, et al. Molecular response, event-free survival, and treatment-free remission in myeloproliferative neoplasms: update and review with insights from MPN Asia 2026. Curr Hematol Malig Rep. 2026;21(1):21. doi:10.1007/s11899-026-00790-5 

This presentation is funded by PharmaEssentia.

©2026 HMP Global. All Rights Reserved.

Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.